| Identification | Back Directory | [Name]
SPARC-related modular calcium-binding protein 2 | [CAS]
1809068-70-9 | [Synonyms]
SMAP2
SMOC2
MST117
SMAP1L
DT-1154
MSTP117
MSTP140
SMAP2,SMAP 2
Rabbit Anti-SMOC2 antibody
Stromal membrane-associated protein 2
Anti-SMOC2 antibody produced in rabbit
Stromal membrane-associated protein 1-like
ANTI-SMOC2 (C-TERM) antibody produced in rabbit
SPARC-related modular calcium-binding protein 2
ANTI-SMAP2 (CENTER) antibody produced in rabbit
Benzenesulfonamide, N-[(1S,2S,3R)-3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)- | [Molecular Formula]
C27H27F3N2O4S | [MDL Number]
MFCD32201049 | [MOL File]
1809068-70-9.mol | [Molecular Weight]
532.57 |
| Chemical Properties | Back Directory | [Boiling point ]
634.7±65.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
Solid | [pka]
10.49±0.60(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity[1][2]. | [in vivo]
SMAP-2 significantly reduces abdominal aortic aneurysms (AAA) incidence and aortic dilation in pro-AAA apolipoprotein E-null (ApoE-/-) mice[2].
SMAP-2 (15 mg/kg; i.g.; daily; 6 days a week; for approximately 14 days) has anti-tumor activity in pancreatic cancer mice model[2].
| Animal Model: | NSG mice, with PANC89 cells xenograft[2] | | Dosage: | 15 mg/kg | | Administration: | Oral gavage, daily, 6 days a week, for approximately 14 days | | Result: | Decreased tumor growth and tumor weight. |
| [References]
[1] Chao Zhang, et al. Abstract 13927: Allosteric Activation of PP2A Inhibits Experimental Abdominal Aortic Aneurysm. 2018. Circulation. 2016;134:A13927.
[2] Brittany L Allen-Petersen, et al. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2019 Jan 1;79(1):209-219. DOI:10.1158/0008-5472.CAN-18-0717 |
|
|